BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
March 27, 2024 16:00 ET
|
BioCardia, Inc.
BioCardia®, Inc. today reported financial results for the year ended December 31, 2023
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
January 03, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
June 08, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
October 12, 2021 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and...
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies
December 30, 2020 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...